Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Objective: Glucose-dependent insulinotropic polypeptide (GIP) is one of the two major incretin factors that regulate metabolic homeostasis. Genetic ablation of its receptor (GIPR) in mice confers protection against diet-induced obesity (DIO), while GIPR neutralizing antibodies produce additive weigh...
Saved in:
Main Authors: | Bin Yang (Author), Vasily M. Gelfanov (Author), Kimberley El (Author), Alex Chen (Author), Rebecca Rohlfs (Author), Barent DuBois (Author), Ann Maria Kruse Hansen (Author), Diego Perez-Tilve (Author), Patrick J. Knerr (Author), David D'Alessio (Author), Jonathan E. Campbell (Author), Jonathan D. Douros (Author), Brian Finan (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
by: Piotr A. Mroz, et al.
Published: (2019) -
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
by: Jonathan E. Campbell
Published: (2021) -
Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant
by: Lucie Yammine, et al.
Published: (2023) -
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022) -
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
by: Gemma Pujadas, et al.
Published: (2022)